Liraglutide Injection
Product Images NDC 72603-745

Product Visual Gallery

This gallery contains 28 technical images submitted to the FDA as part of the official labeling for Liraglutide (NDC 72603-745). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Northstar Rx Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Principal Display Panel – Liraglutide Injection 18 mg Per 3 mL 2-pack Carton (Lira Carton 2pack Ns V1)

Liraglutide Injection 18 mg per 3 mL (6 mg per mL) subcutaneous injection carton from NorthStar Rx LLC. The package contains 2 pre-filled pens, each delivering doses of 0.6 mg, 1.2 mg, or 1.8 mg. The label includes storage instructions to refrigerate and not freeze and indicates single-patient use only with enclosed medication guide information.*

FDA Label Image

Principal Display Panel – Liraglutide Injection 18 mg Per 3 mL 3-pack Carton (Lira Carton 3pack Ns V1)

Packaging label for Liraglutide Injection 18 mg per 3 mL (6 mg per mL) by NorthStar Rx LLC. It contains 3 pre-filled pens for subcutaneous injection, with single-patient use instructions. The label includes dosing information, storage instructions to refrigerate but not freeze, and states the product is sterile and nonpyrogenic. The label also includes barcodes and manufacturer details.*

FDA Label Image

Structural Formula (Lira Fig 1)

Chemical structure diagram illustrating the sequence of amino acids in liraglutide, including a C-16 fatty acid (palmitoyl) modification attached to a glutamic acid residue, highlighting key amino acids involved in its molecular configuration.*

FDA Label Image

Figure 2 (Lira Fig 2)

A line chart comparing insulin secretion rate (ISR) in pmol/kg/min versus plasma glucose levels in mg/dL for Liraglutide 6 mg/mL injection and placebo. The chart shows ISR increasing with plasma glucose for both treatments, with Liraglutide consistently higher than placebo across glucose concentrations from about 85 to 215 mg/dL.*

FDA Label Image

Figure 3 (Lira Fig 3)

A line graph comparing mean HbA1c percentage over 52 weeks for three treatments: Glimepiride, Liraglutide 1.2 mg, and Liraglutide 1.8 mg. The graph shows changes in HbA1c levels from baseline to week 52, with Liraglutide doses reducing HbA1c more than Glimepiride. Statistical significance is noted for the liraglutide groups versus glimepiride.*

FDA Label Image

Figure 4 (Lira Fig 4)

A line graph comparing mean HbA1c percentage over 26 weeks for Liraglutide 1.2 mg, Liraglutide 1.8 mg, and Sitagliptin 100 mg. The graph shows time in weeks on the x-axis and mean HbA1c (%) on the y-axis, illustrating changes in blood sugar control across treatment groups, with Liraglutide doses showing greater reductions than Sitagliptin.*

FDA Label Image

Flow Check Symbol (Lira Flow Check)

Liraglutide 6 mg/mL injection packaging label for subcutaneous use with a single-dose pen device. The carton is white with blue and green accents and displays the NorthStar Rx LLC labeler name. The package contains one 3 mL pen delivering 18 mg in 3 mL.*

FDA Label Image

Figure A (Lira Ifu A)

An instructional illustration showing hands holding and preparing a liraglutide injection pen, with an arrow indicating the direction to pull or remove a component, likely the protective cap from the pen before use.*

FDA Label Image

Figure B (Lira Ifu B)

An instructional illustration shows a hand holding a liraglutide injection pen. The thumb and forefinger grip the pen while an arrow indicates pulling or removing the cap from the pen tip, demonstrating part of the preparation process for a subcutaneous injection.*

FDA Label Image

Figure C (Lira Ifu C)

An instructional illustration showing a hand removing the cap from the needle end of a liraglutide injection pen. The image includes a blue arrow indicating the direction to pull the cap off, emphasizing proper preparation for subcutaneous injection.*

FDA Label Image

Figure D (Lira Ifu D)

Illustration showing a hand holding a liraglutide injection pen with a needle cap being removed by pulling it straight off, as indicated by a large arrow pointing away from the pen.*

FDA Label Image

Figure E (Lira Ifu E)

An instructional illustration showing a pair of hands holding a liraglutide injection pen. The image highlights the flow check symbol selected on the pen's display, indicating the readiness of the device for use.*

FDA Label Image

Figure F (Lira Ifu F)

An instructional illustration showing a hand holding a liraglutide injection pen near the needle tip, with motion lines indicating shaking or vibration action of the pen before use.*

FDA Label Image

Figure G (Lira Ifu G)

An instructional illustration showing a hand holding a liraglutide injection pen and pulling the dose window knob upward. The pen is indicated as a subcutaneous injection device for liraglutide 6 mg/mL by NorthStar Rx LLC. The image focuses on adjusting the dose selector on the pen.*

FDA Label Image

Figure H (Lira Ifu H)

An instructional illustration showing hands holding a pen-like injection device, with an arrow indicating removal or extension of a cap or cover, likely related to preparing a liraglutide injection pen for use.*

FDA Label Image

Figure I (Lira Ifu I)

Instructional illustration showing a hand holding a liraglutide injection pen with the thumb and forefinger removing or adjusting a cap or cover from the pen needle area. The blue arrow indicates the motion direction to pull or lift the cap off the pen needle.*

FDA Label Image

Figure J (Lira Ifu J)

An instructional illustration showing a hand removing the cap from the needle of a subcutaneous injection pen device for Liraglutide 6 mg/mL, a human prescription drug by NorthStar Rx LLC.*

FDA Label Image

Figure K (Lira Ifu K)

An instructional illustration showing a close-up of a hand holding a liraglutide subcutaneous injection pen near a skin surface. A blue arrow indicates the direction for injecting or preparing to inject the medication with the pen device.*

FDA Label Image

Figure L (Lira Ifu L)

Illustration showing hands adjusting the dose selector on a liraglutide injection pen with a close-up of the dose window. Below are three dose selections displayed: 0.6 mg, 1.2 mg, and 1.8 mg, indicating possible dosage settings for subcutaneous injection.*

FDA Label Image

Figure M (Lira Ifu M V2)

An anatomical illustration of a human male figure showing recommended injection sites for Liraglutide, including the upper arms, stomach, and thighs, with shaded areas indicating the locations for subcutaneous injections.*

FDA Label Image

Figure N (Lira Ifu N V2)

Illustration showing a hand holding a Liraglutide injection pen while pressing down the blue end cap. The label on the pen indicates a 1.8 mg dose. This image is part of instructions for using the liraglutide 6 mg/mL subcutaneous injection by NorthStar Rx LLC.*

FDA Label Image

Liraglutide Needle (Lira Ifu Needle)

An instructional diagram showing components of a needle assembly for injection. It includes labeled parts: outer needle cap, inner needle cap, needle, and protective tab. The illustration is meant to visually explain each part of the needle setup.*

FDA Label Image

Figure O (Lira Ifu O V2)

An instructional illustration showing a hand pressing down on the top of a liraglutide injection pen, with a downward arrow indicating the action. A stopwatch graphic displays 6 seconds, suggesting to hold the pen for this duration during injection.*

FDA Label Image

Figure P (Lira Ifu P V2)

An instructional illustration showing a subcutaneous injection technique using a pen device. The image depicts the pen needle positioned at skin level with an upward arrow indicating the direction or placement method for the injection.*

FDA Label Image

Liraglutide Injection Pen (Lira Ifu Pen)

Illustration of a Liraglutide injection pen identifying various parts including the pen cap, rubber stopper, cartridge tip, cartridge with scale, dose selector with pointer, dose display, dose button, and a flow check symbol. The pen is used for subcutaneous injection of liraglutide.*

FDA Label Image

Figure Q (Lira Ifu Q V2)

An instructional illustration showing the removal of the needle cap from a liraglutide subcutaneous injection pen. The cap is held separately to the left, with an arrow indicating its direction of removal from the pen's needle.*

FDA Label Image

Figure R (Lira Ifu R)

An instructional illustration showing hands holding an injection pen device. The image depicts the action of removing a cap or protective cover from the pen, indicated by a directional arrow pointing away from the device tip.*

FDA Label Image

Principal Display Panel – Liraglutide Injection 18 mg Per 3 mL Syringe Label (Lira Syringe Ns V1)

Liraglutide Injection 6 mg/mL subcutaneous injection label from NorthStar Rx LLC. The label states 18 mg per 3 mL per pre-filled pen for single-patient use only, with storage instructions to refrigerate before use and not freeze. Lot and expiration fields are blank.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.